InvestorsHub Logo
Followers 31
Posts 3757
Boards Moderated 0
Alias Born 01/29/2012

Re: Waitforit53 post# 35695

Monday, 08/22/2016 3:13:24 PM

Monday, August 22, 2016 3:13:24 PM

Post# of 48316
Regarding valuation, AbbVie recently acquired Stemcentrx for $10.2B. Among its other pipelines, a phase 2 trial in small cell lung cancer was its furthest one. If OncoSec's p2b melanoma combo data hits a home run, turning absolute non-responders into responders, a $4B valuation will not be something unattainable IMO given the platform's potential to create responders in other cancer indications as well, including hard to reach internal ones.